binding is inhibited (6, 10 ). An NH 2 -terminal domain of ICAT binds to armadillo repeats 10-12 of ␤-catenin, whereas a COOH-terminal domain of ICAT binds to the groove formed by armadillo repeats 5-9, this latter site being crucial for the binding of TCF and, coincidentally, of E-cadherin. Experimental evidence has confirmed that ICAT does block binding of ␤-catenin to TCF and blocks the function of ␤-catenin in Wnt signaling (10) , but what about interactions with E-cadherin? On the basis of the structural data, having ICAT bound in the groove of ␤-catenin should also potentially interfere with E-cadherin binding. Previously it was shown that ICAT could block the binding of C-cadherin to ␤-catenin in vitro; however, overexpression of ICAT in Xenopus oocytes did not disrupt adhesion or show biochemical evidence for an in vivo inhibition of C-cadherin/␤-catenin complexes by ICAT (10).
Gottardi and Gumbiner (9) have now more closely explored the biology of ICAT in cells and its potential for involvement in regulating cadherin-based adhesion through inhibiting the interaction of E-cadherin with ␤-catenin. An important contribution of this article is to reveal some of the basic physiology of ICAT's expression, localization, and response to Wnt signaling in cells and tissues. Immunostaining of ICAT is present in the cytoplasm and nucleus of cells (9) . Other salient biochemical features of ICAT are its relative abundance in cells and the fact that a large proportion of soluble ␤-catenin is stably bound to ICAT in cells. ICAT is thus well positioned to be a major regulator of ␤-catenin, particularly during Wnt signaling, which appears to increase the amount of ␤-catenin bound to ICAT. By staining sections of intestinal mucosa, the expression of endogenous ICAT was examined in an epithelium that undergoes Wnt-induced differentiation along the length of the villus. The data show that expression of ICAT correlates inversely with the known transcriptional activity of ␤-catenin, i.e., ICAT is predomintantly expressed in the villus epithelial cells (where ␤-catenin is not active in Wnt-induced transcription) and is diminished in crypt cells (where ␤-catenin is transcriptionally active). This provides a physiological context for correlating ICAT's expression with ␤-catenin function and with cell differentiation. However, ICAT expression levels in different cell lines did not correlate with Wnt signaling or with ␤-catenin levels, suggesting that ICAT itself is probably not a Wnt responsive gene. These results preserve the growing reputation of ICAT as a competitive inhibitor of ␤-catenin in its role as a transcriptional activator and as a regulator in Wnt signaling pathways.
What next for ICAT? As a possible alternative binding partner for the central groove and same armadillo repeats of ␤-catenin, E-cadherin is notably absent, and apparently actively excluded, from the ICAT/␤-catenin complexes precipitated from cell extracts. New data (9) further confirm the ability of ICAT to block ␤-catenin binding to the cytoplasmic tail domain of E-cadherin in vitro. There is a clear consensus that the precise binding domains on ␤-catenin for ICAT and for E-cadherin do overlap, and there is the potential for competitive binding. Gottardi and Gumbiner (9) have gone on to show in vivo that, indeed, ICAT can affect the ␤-catenin/E-cadherin interaction, but only as qualified by the physiology of the cells. At steady state, in Madin-Darby canine kidney cells stably overexpressing ICAT, there was no evidence for altered ␤-catenin binding to E-cadherin and no overt effect on cadherin-based adhesion. However, in cells treated with hepatocyte growth factor (scatter factor; HGF), ICAT overexpression reduced E-cadherin levels, increased the ␤-catenin bound to ICAT, and enhanced cell scattering. Thus ICAT can act as an inhibitor of a second function of ␤-catenin: its role in cadherinbased adhesion. As suggested by these data, ICAT might only perform this inhibition in growth-stimulated or motile cells in which there is the requirement to downregulate adhesion. One mechanism suggested by the authors (9) for this discriminate binding of ICAT to ␤-catenin is the reduced affinity of binding between E-cadherin and ␤-catenin brought about by phosphorylation of both proteins after growth factor stimulation (11) . Subsequent to this in the response to growth factor binding, E-cadherin is endocytosed (7) . The stoichiometry of the E-cadherin/␤-catenin complex changes during endocytosis (14), providing another possible opportunity for ICAT binding to sequester ␤-catenin and reduce adhesive capacity.
The mechanisms available for downregulating cadherinbased adhesion are only now beginning to be understood. During morphogenesis or in wound healing, cell-cell adhesion is downregulated, and several mechanisms have been identified for reducing adhesion based on regulating the cadherins themselves. The endocytosis and recycling of E-cadherin remove cadherin/catenin complexes from the cell surface and provide one efficient mechanism for transiently regulating adhesion (1, 13, 14, (16) (17) (18) . In epithelial-to-mesenchymal transition and in tumorigenesis there is a more permanent loss of adhesion through SNAIL-and SLUG-mediated transcriptional repression of E-cadherin (2, 4, 15) and through growth factorinduced ubiquitination, endocytosis, and degradation of Ecadherin (7) . A fully detailed understanding of these endocytic and degradative pathways has yet to be pieced together, and it will be interesting to see whether ICAT is directly involved.
Thus, of the three main functional complexes formed by ␤-catenin in cells, ICAT selectively participates in two of them. ICAT is not, however, a three-way inhibitor. ICAT does not directly regulate the cellular levels of ␤-catenin by affecting the interaction of ␤-catenin with APC for its degradation, and it does not compete with APC for binding (9) . APC can bind to soluble ␤-catenin simultaneously with ICAT, in keeping with predictions from APC's specific and slightly offset binding site (20) . Through sequestering ␤-catenin, ICAT inhibits both Wnt responsive gene expression and cadherin-based cell adhesion, each of which is an avenue to a role for ICAT in tumorigenesis. ICAT is not the singly selective inhibitor and drug target previously proposed (10) but may in fact be more powerful in both respects because of its dual specificity. The inappropriate transcriptional activity of ␤-catenin is implicated in a number of cancers, through either mutations that block GSK3␤ phosphorylation or mutations of APC/axin (3), and E-cadherin is typically downregulated in metastatic tumours (5) . Intriguingly, ICAT is overexpressed in some tumors (12) .
Future studies should no doubt provide new insights into how manipulation of ICAT might be exploited through one or both of its inhibitory actions for new therapeutic approaches in cancer.
